Clinical trials: Psychoses
Schizophrenia Disorders
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.
- Trial name
- NCT01163227
- Testing
- AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson Disease Psychosis
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
A study to evaluate the safety and tolerability of SEP-363856 in subjects with Parkinson's Disease Psychosis. This study is accepting male and female participants 55 years of age and older who have been diagnosed with Parkinson's…
- Trial name
- NCT02969369
- Testing
- SEP-363856
- Where
- 24 sites in United States
- Volunteers
- 39 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Schizophrenia
A Trial to Assess the Antipsychotic Efficacy of ITI-007
The study will be conducted as a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
- Trial name
- NCT02282761
- Testing
- ITI-007
- Where
- 11 sites in United States
- Volunteers
- 450 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia
Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
To assess the effectiveness of aripiprazole once-monthly in the maintenance treatment of patients with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text…
- Trial name
- NCT01795547
- Testing
- Aripiprazole and aripiprazole once-monthly, Paliperidone and paliperidone palmitate
- Where
- 2 sites in United States
- Volunteers
- 295 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Treatment of Social Cognition in Schizophrenia Trial
This study is a multi-site, prospective, parallel arm, double-blind, randomized, controlled clinical trial to assess the efficacy of an experimental software program targeting social cognitive abilities versus a computer-based…
- Trial name
- TRuSST (NCT02246426)
- Testing
- Computerized plasticity-based adaptive cognitive training, Commercially available computerized training
- Where
- 4 sites in United States
- Volunteers
- 149 people
- Sponsor
- Posit Science Corporation
Schizophrenia
A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices
The purpose of this clinical research study is to evaluate if Aripiprazole will prove to be effective, safe and well tolerated in the treatment of patients with schizophrenia who are treated in a general psychiatric setting.
- Trial name
- NCT00237939
- Testing
- Aripiprazole
- Where
- 20 sites in Belgium, France and 3 more
- Volunteers
- 1,200 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorders
An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment
The purpose of this study is to evaluate the efficacy and safety of long-acting risperidone microspheres (small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various…
- Trial name
- NCT00526877
- Testing
- Risperidone
- Where
- Taiwan
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Schizophrenia or Schizoaffective Disorder
Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581
The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body, safety and tolerability of AMG 581 in healthy participants and subjects with schizophrenia.
- Trial name
- FIH (NCT02567370)
- Testing
- AMG 581
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Amgen
Schizophrenia
A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia
The purpose of this study is to evaluate the long-term safety and tolerability and the maintenance of effectiveness of a slow, extended-release oral formulation of paliperidone administered once daily to patients diagnosed with…
- Trial name
- NCT00210769
- Testing
- paliperidone ER Oros
- Volunteers
- 203 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Paranoid Schizophrenia
MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
The purpose of this study is to determine the safety and effectiveness of an investigational drug MK0249 for the treatment of the cognitive impairment in patients with schizophrenia.
- Trial name
- NCT00506077
- Testing
- MK0249
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Schizo-affective Disorder
Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
The study will be a 6-month, open-label, multiple center study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone…
- Trial name
- NCT02658357
- Testing
- Risperidone Implant
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Braeburn Pharmaceuticals
Schizophrenia
A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.
Study to compare PK of a new 120mg tablet with two 60mg tablets. This is required because we plan to have only single tablets administered in the later phase clinical trials but we have not had a 120mg strength before.
- Trial name
- NCT00500201
- Testing
- SB- 773812 60 mg, SB- 773812 120 mg
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.
- Trial name
- NCT02694328
- Testing
- ALKS 3831, Olanzapine
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 561 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)
This is a randomized, double-blind, 2-part clinical study of the safety, tolerability and pharmacokinetics of alternate elpipodect titration regimens.
- Trial name
- NCT04506905
- Testing
- Elpipodect
- Where
- 6 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Psychotic Disorders
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document both short-term, as well as long-term efficacy and safety of a long-acting injectable formulation of risperidone, in comparison with olanzapine for the treatment of patients with…
- Trial name
- NCT00236457
- Testing
- risperidone
- Volunteers
- 629 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Efficacy Study on Cognitive Functions in Schizophrenic Patients
Primary objectives To compare neurocognitive effects of amisulpride with those of risperidone in patients with chronic schizophrenia, as assessed by the general cognitive index, a measure of overall cognitive functioning in…
- Trial name
- AMIMIND (NCT00761670)
- Testing
- amisulpride and risperidone
- Where
- Hungary
- Volunteers
- 37 people
- Sponsor
- Sanofi
Alzheimer's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
This study will evaluate the safety and efficacy of pimavanserin 40 mg compared to placebo in patients with Alzheimer's disease psychosis.
- Trial name
- NCT02035553
- Testing
- Pimavanserin tartrate
- Where
- United Kingdom
- Volunteers
- 181 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Affective Psychosis, Bipolar, Mania
Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.
Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.
- Conditions
- Affective Psychosis, Bipolar, Mania, Manic-Depressive Psychosis
- Trial name
- NCT00454883
- Testing
- ziprasidone
- Volunteers
- 379 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of the negative symptoms of schizophrenia
- Trial name
- NCT02970305
- Testing
- Pimavanserin
- Where
- 101 sites in United States, Bulgaria and 8 more
- Volunteers
- 403 people
- Sponsor
- ACADIA Pharmaceuticals Inc.